Investment Rating - The investment rating for Sunny Optical is maintained at Neutral with a 12-month target price of HK$63.50, based on a P/E multiple of 23.3x for 2025E [6][9]. Core Insights - Sunny Optical's September shipments showed a year-on-year increase of 6% for handset lenses, while camera module shipments decreased by 30% year-on-year. Vehicle lens shipments increased by 13% year-on-year [1][2]. - The company is expected to improve its gross margin (GM) to 17.5% in the second half of 2024, up from 14.1% in the second half of 2023 and 17.2% in the first half of 2024, driven by product mix upgrades towards mid and high-end smartphone projects [1][4]. - The overall shipment performance for the first nine months of 2024 is largely in line with estimates, with handset lens shipments tracking 77% of the 2024 estimates, vehicle lens at 78%, and camera modules at 74% [2][4]. Shipment Performance Summary - Handset lens shipments in September were 119 million units, a decrease of 4% month-on-month but an increase of 6% year-on-year, leading to a total of 993 million units for the first nine months of 2024, representing a 20% year-on-year growth [2][4]. - Camera module shipments were 37 million units in September, down 30% year-on-year, with a total of 409 million units for the first nine months of 2024, reflecting a 3% year-on-year increase [4]. - Vehicle lens shipments reached 9 million units in September, up 13% year-on-year, contributing to a total of 80 million units for the first nine months of 2024 [2][4]. Financial Projections - Revenue projections for Sunny Optical are estimated to reach RMB 37.63 billion in 2024, with an expected increase to RMB 45.36 billion in 2025 and RMB 53.74 billion in 2026 [9]. - The earnings per share (EPS) is projected to be RMB 2.08 in 2024, increasing to RMB 2.56 in 2025 and RMB 3.24 in 2026 [9].

8 October 2024 | 6:23AM HKT CSPC Pharma (1093.HK): First overseas BD deal with MNC; Licensing-out a metabolism drug Licensing-out a pre-clinical metabolism asset to AstraZeneca (AZ): CSPC announced plans to license out the global rights of YS2302018, a lipoprotein(a) (Lpa) small molecule inhibitor in pre-clinical stage and any product that contains YS2302018, which could refer to combination therapy, to AstraZeneca for: 1) an upfront payment of US$100mn, which we see as quite meaningful for a pre-clinical a ...

7 October 2024 | 8:13PM HKT | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|----------- ...

Investment Rating - The report assigns an "Overweight" (OW) rating to Yuexiu Property Co Ltd, indicating a favorable outlook compared to peers [1][3][5]. Core Insights - Yuexiu Property is expected to outperform its peers in sales, profitability, and dividend prospects due to its high-quality sellable resources and superior land reserve channels [1][5]. - The company has a strong financial position and low liquidity risk, supported by its state-owned enterprise (SOE) background [1][6]. - The report anticipates a target price of HKD 5.48, representing a potential upside of approximately 20% from the current price [5][6]. Summary by Sections Sales Growth and Land Reserves - Yuexiu Property has approximately RMB 330 billion in unsold sellable resources, with over 65% located in first-tier cities and more than 30% in second-tier cities [5][6]. - The company has maintained a land acquisition strategy that allows it to purchase land at lower costs, with 60% of its unsold resources acquired during a period of significant price adjustments in 2022 [5][6]. Financing and Liquidity - The company has maintained a net debt ratio of 60% and a cash coverage ratio of 1.5 times for short-term debt, indicating strong liquidity [1][6]. - Yuexiu Property benefits from a diversified financing capability, with an average financing cost of 3.57%, one of the lowest among its peers [6]. Management Incentives and Dividend Yield - The management has implemented equity incentive plans to align interests with shareholders, aiming for a stable dividend payout ratio of 40% [2][5]. - The expected dividend yield for 2024-2026 is projected to be between 7-9%, which is among the highest in the industry [2][5]. Valuation and Market Position - The report highlights that Yuexiu Property's current valuation appears attractive at 5.0 times the 2025 price-to-earnings ratio, compared to 5.1 times for its H-share SOE peers [5][6]. - The company is expected to increase its market share to 1.3% in 2024, up from 1.2% in 2023, positioning it among China's top ten developers [5][6].

高盛：海底捞股价调整反映下行风险，股东回报提供支持 ...

高盛：华虹半导体CFO电话会议要点12英寸新产线年投产,812英寸产能利用率保持高位;维持买入 ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 21 June 2024 | 7:17AM HKT The 720: China Internet - 618 Shopping Festival, Sanhua, Japan Retail, Global Smartphone, Hon Hai, Hua Hong, China Macro In Focus | China Internet - 618 Shopping Festival Michael Snaith +852-2978-0455 | michael.snaith@gs.com China Internet - 618 Shopping Festival 5 key highlights - Buy BABA, PDD, Kuaishou Goldman Sachs (Asia) L.L.C. Caleb Chan (on CL). With China’s 618 Shopping Festival (the longest yet) now concluded (on +852-2978-0790 | caleb.chan@gs. ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 7 June 2024 | 9:51PM HKT Miniso (MNSO): Consumer & Leisure Corporate Day: Recent trends continue to be solid in both China/overseas; Buy Bottom line: We hosted Miniso management at our Consumer & Leisure Corporate Michelle Cheng +852-2978-6631 | Day on Jun 7. Investors were mostly focused on: 1) recent trends: In China, Miniso’s michelle.cheng@gs.com Goldman Sachs (Asia) L.L.C. SSS performance was healthy, fluctuating around 100% of 2023 level YTD despite Xinyu Ruan overall soft ...

更多资料加入知识星球：水木调研纪要关注公众号：水木纪要 Goldman Equity Sachs Research 28 May 2024 | 7:29AM HKT CSPC Pharma (1093.HK) NBP VBP cliff vs. new product cycle - risks reflected; earnings recovery fol potential re-rating: Reiterate Buy 12m Price Target: HK$10.26 1093.HK Price: HK$6.89 Upside: 48.9% Ziyi Chen +852-2978-0526zivi Goldman Sachs (Asia (from HK$9.73). NBP risk manageable: We see low chance for a VBP cliff for NBP in '24-26e, and believe the worst case scenario beyond '26 (i.e. VBP in '27, sales cut by Rmb5-6bn) has ...

Global Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: Tencent Holdings (HK$383.60) Goldman Sachs has received compensation for non-investment banking services during the past 12 months: Tencent Holdings (HK$383.00) Goldman Sachs had an investment banking services client relationship during the past 12 months with: Tencent Holdings (HK$383.60) Goldman Sachs had a non-invastment banking securities-related services client relationship duri ...